Inflammation
Conditions
Keywords
Senolytic
Brief summary
This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete electronic surveys on health indicators at baseline, and days 3 and 7. All procedures are conducted remotely, with no in-person visits, to collect real-world evidence.
Detailed description
Objectives Within-group changes in outcomes will be compared from baseline to the end of the study period. Primary Outcome Measures: Biomarkers in blood, measured using the Olink Target 48 Cytokine panel: Tumor Necrosis Factor (TNF) Interleukin-1 Beta (IL1B) Interleukin-8 (CXCL8) Vascular Endothelial Growth Factor A (VEGFA) Secondary Outcome Measures: Remaining biomarkers in the Olink Target 48 Cytokine panel 36-Item Short Form Health Survey (SF-36) Frailty Index for Elders (FIFE) Depression Anxiety Stress Scale-21 (DASS-21) Side effect profile including: Number, type, severity, causality, and outcome of adverse events or unanticipated problems Symptoms of aging, assessed by: Aging Male Symptom scale Aging Female Symptom scale Participant Details: Study Duration per Participant: 7 days Total Number of Participants: 40
Interventions
DIETARY_SUPPLEMENTQualia Senolytic
Qualia Senolytic manufactured by Qualia Life Science
Sponsors
Qualia Life Sciences
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
45 Years to 79 Years
Healthy volunteers
Yes
Inclusion criteria
* Provide voluntary, written, informed consent to participate in the study * Agree to provide a valid cell phone number and are willing to receive communications through text. * Healthy adults 45 - 79 years of age Can read and write English * Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly. * Willing to self-administer the fingerstick test kit at home for both a baseline and post-intervention blood sample, and to complete a release form that gives NHC access to the results of these tests. * Willing to complete questionnaires, records, and diaries associated with the study.
Exclusion criteria
* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial * Known food intolerances/allergy to any ingredients in the product * Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer * Having had a significant cardiovascular event in the past 6 months * Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines * On immunosuppressive therapy * Individuals who were deemed incompatible with the test protocol * Adults lacking capacity to consent
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Olink Target 48 Cytokine panel - TNF, IL1B, CXCL8, VEGFA | 1 week | Biomarkers in blood, measured using the Olink Target 48 Cytokine panel: Tumor Necrosis Factor (TNF) Interleukin-1 Beta (IL1B) Interleukin-8 (CXCL8) Vascular Endothelial Growth Factor A (VEGFA) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 36-Item Short Form Health Survey (SF-36) | 1 week | — |
| Frailty Index for Elders (FIFE) | 1 week | — |
| Remaining biomarkers in the Olink Target 48 Cytokine panel | 1 week | — |
| Aging Male/Female Symptom scale | 1 week | — |
| Side effect profile as measured by a custom Safety and Tolerability survey | 1 week | Number of participants with treatment-related adverse events as assessed by a score of 3 or greater on the Safety and Tolerability survey |
| Depression Anxiety Stress Scale-21 (DASS-21) | 1 week | — |
Countries
United States
Contacts
Primary ContactWilliam Scuba
Outcome results
None listed